Evidence map›Paper›PMID 39549757›Full record

ArticleInternational journal of radiation oncology, biology, physics2025

Outcomes After Palliative Radiation Therapy in Patients With Symptomatic Locoregionally Advanced Breast Cancer.

Luisa E Jacomina, David M Swanson, Melissa P Mitchell, Wendy A Woodward, Benjamin D Smith, Karen E Hoffman, Chelain R Goodman, Haven R Garber, Susie X Sun, Timothy A Yap and 7 more

Abstract readMulticenter Study
In one paragraph

Article in International journal of radiation oncology, biology, physics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Locally advanced breast cancer: primary ultra-hypofractionated radiotherapy for inoperable or frail patients.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026
    Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Luisa E JacominaDepartments of Radiation Oncology; Breast Radiation Oncology. Electronic address: luisajacomina@gmail.com.
David M SwansonDepartments of Radiation Oncology; Biostatistics.
Melissa P MitchellBreast Radiation Oncology.
Wendy A WoodwardBreast Radiation Oncology.
Benjamin D SmithBreast Radiation Oncology.
Karen E HoffmanBreast Radiation Oncology; Genitourinary Radiation Oncology.
Chelain R GoodmanBreast Radiation Oncology.
Haven R GarberBreast Medical Oncology.
Susie X SunBreast Surgical Oncology.
Timothy A YapInvestigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Funda Meric-BernstamInvestigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Isidora Y ArzuDepartments of Radiation Oncology; Breast Radiation Oncology.
Elizabeth S BloomDepartments of Radiation Oncology; Breast Radiation Oncology.
Pamela J SchlembachDepartments of Radiation Oncology; Breast Radiation Oncology.
Eric A StromBreast Radiation Oncology.
Michael C StauderBreast Radiation Oncology.
Simona F ShaitelmanBreast Radiation Oncology.

Funding

Paul Calabresi Clinical Oncology AwardK12CA088084 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI David S. Hong, Scott Kopetz · 2000 to 2026
$14.0M
Project 3: Inhibiting Oxidative Phosphorylation in Pancreatic CancerP50CA221707 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KOPETZ, SCOTT · 2019 to 2023
$11.0M
NCI NIH HHS K12 CA088084NCI NIH HHS P50 CA221707
6 · The paper itself

Abstract

purposeSymptomatic locoregionally advanced breast cancer (SLABC) can cause troublesome pain or wound complications that negatively impact quality of life. Although palliative radiation therapy (RT) can minimize tumor-related symptoms, how best to tailor RT to achieve the most meaningful and durable response is not well defined. METHODS AND MATERIALS: This is a single institution, multi-site retrospective review of patients with SLABC treated between 2016 and 2023 with palliative RT to symptomatic disease in the breast, chest wall, and/or regional lymph node basins. Overall survival (OS), locoregional control (LC), clinical and radiographic treatment response, overall pain scores, and treatment-related toxicities were analyzed.

resultsA total of 164 patients with a median age of 57 years were analyzed with a median follow-up time of 4.97 months. In total, 86% had distant metastases. The most common presenting symptom was pain (87%), followed by ulcerating or fungating lesion (76%) and discharge (45%). The median cumulative biologically effective dose to the gross tumor volume (BED

conclusionsIn this large series of patients with SLABC, palliative RT was effective at relieving locoregional symptoms with acceptable toxicity, with the likelihood of symptom improvement associated with radiation dose. Survival of these patients remains poor, highlighting the importance of palliative care strategies that minimize overall symptom burden while maximizing quality of life.

Indexed as

Breast NeoplasmsPalliative CareAdultAgedAged, 80 and overCancer PainFemaleHumansMiddle AgedQuality of LifeRadiotherapy DosageRetrospective StudiesTreatment Outcome

Identifiers

PMID39549757
PMCPMC12172089

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.